Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent developments in topoisomerase-targeted cancer chemotherapy
Kirk E. Hevener, Tatsiana A. Verstak, Katie E. Lutat, et al.
Acta Pharmaceutica Sinica B (2018) Vol. 8, Iss. 6, pp. 844-861
Open Access | Times Cited: 204

Showing 1-25 of 204 citing articles:

Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets
Žiga Skok, Nace Zidar, D. Kikelj, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 3, pp. 884-904
Open Access | Times Cited: 171
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
Caroline Molinaro, Alain Martoriati, Lydie Pélinski, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 2863-2863
Open Access | Times Cited: 152
Target-based anticancer indole derivatives and insight into structure‒activity relationship: A mechanistic review update (2018–2021)
A M Dhiman, Rupam Sharma, Rajesh K. Singh
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 7, pp. 3006-3027
Open Access | Times Cited: 113
Emerging trends in organ-on-a-chip systems for drug screening
Yanping Wang, Yanfeng Gao, Yongchun Pan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2483-2509
Open Access | Times Cited: 58
Anticancer mechanism of coumarin-based derivatives
Anand Kumar Yadav, Ramina Maharjan Shrestha, Paras Nath Yadav
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116179-116179
Closed Access | Times Cited: 35
Cellular consequences of arginine methylation
Benjamin M. Lorton, David Shechter
Cellular and Molecular Life Sciences (2019) Vol. 76, Iss. 15, pp. 2933-2956
Open Access | Times Cited: 132
Journey of anthraquinones as anticancer agents – a systematic review of recent literature
M. Shaheer Malik, Reem I. Alsantali, Rabab S. Jassas, et al.
RSC Advances (2021) Vol. 11, Iss. 57, pp. 35806-35827
Open Access | Times Cited: 101
DNA topoisomerases as molecular targets for anticancer drugs
Kamila Buzun, Anna Bielawska, Krzysztof Bielawski, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2020) Vol. 35, Iss. 1, pp. 1781-1799
Open Access | Times Cited: 93
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
Lukáš Górecki, Martin Andrš, Martina Řezáčová, et al.
Pharmacology & Therapeutics (2020) Vol. 210, pp. 107518-107518
Closed Access | Times Cited: 86
<p>The Antibacterial Activity and Mechanism of Action of Luteolin Against <em>Trueperella pyogenes</em></p>
Yuru Guo, Yan Liu, Zehui Zhang, et al.
Infection and Drug Resistance (2020) Vol. Volume 13, pp. 1697-1711
Open Access | Times Cited: 85
Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer
Sibusiso Alven, Xhamla Nqoro, Buhle Buyana, et al.
Pharmaceutics (2020) Vol. 12, Iss. 5, pp. 406-406
Open Access | Times Cited: 82
Highlights in Resistance Mechanism Pathways for Combination Therapy
João Marcos de Azevedo Delou, A. S. Souza, Leonel Cardozo de Menezes e Souza, et al.
Cells (2019) Vol. 8, Iss. 9, pp. 1013-1013
Open Access | Times Cited: 80
Perspectives and controversies regarding the use of natural products for the treatment of lung cancer
Tingting Wen, Lei Song, Shucheng Hua
Cancer Medicine (2021) Vol. 10, Iss. 7, pp. 2396-2422
Open Access | Times Cited: 60
Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation
Muhammad Bilal Ahmed, Salman Ul Islam, Abdullah A. A. Alghamdi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15765-15765
Open Access | Times Cited: 47
Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
Prasanna Anjaneyulu Yakkala, Naveen Reddy Penumallu, Syed Shafi, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1456-1456
Open Access | Times Cited: 36
Topoisomerase II inhibitors design: Early studies and new perspectives
Hadeer K. Swedan, Asmaa E. Kassab, Ehab M. Gedawy, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106548-106548
Closed Access | Times Cited: 26
Recent updates on thienopyrimidine derivatives as anticancer agents
Menna Tallah M. Sayed, Rasha A. Hassan, Peter A. Halim, et al.
Medicinal Chemistry Research (2023) Vol. 32, Iss. 4, pp. 659-681
Open Access | Times Cited: 24
Molecular regulation of the key specialized metabolism pathways in medicinal plants
Min Shi, Zhang Siwei, Zizhen Zheng, et al.
Journal of Integrative Plant Biology (2024) Vol. 66, Iss. 3, pp. 510-531
Open Access | Times Cited: 16
Discovery of New Schiff Bases Tethered Pyrazole Moiety: Design, Synthesis, Biological Evaluation, and Molecular Docking Study as Dual Targeting DHFR/DNA Gyrase Inhibitors with Immunomodulatory Activity
Ashraf S. Hassan, Ahmed Askar, Ahmed M. Naglah, et al.
Molecules (2020) Vol. 25, Iss. 11, pp. 2593-2593
Open Access | Times Cited: 65
Therapeutic Potential of Ursonic Acid: Comparison with Ursolic Acid
Juhyeon Son, Sang Yeol Lee
Biomolecules (2020) Vol. 10, Iss. 11, pp. 1505-1505
Open Access | Times Cited: 53
Research progress on the biosynthesis and metabolic engineering of the anti-cancer drug camptothecin in Camptotheca acuminate
Xiaoxuan Fan, Xinting Lin, Qingyan Ruan, et al.
Industrial Crops and Products (2022) Vol. 186, pp. 115270-115270
Closed Access | Times Cited: 32
Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors
Jung Yoon Jang, Donghwan Kim, Nam Deuk Kim
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8457-8457
Open Access | Times Cited: 20
Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems
Ali Dehshahri, Milad Ashrafizadeh, Elham Ghasemipour Afshar, et al.
Pharmacological Research (2019) Vol. 151, pp. 104551-104551
Closed Access | Times Cited: 52
The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage
Chao Mei, Lin Lei, Liming Tan, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 125, pp. 109875-109875
Open Access | Times Cited: 44
Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs
Emma Baglini, Silvia Salerno, Elisabetta Barresi, et al.
European Journal of Pharmaceutical Sciences (2020) Vol. 156, pp. 105594-105594
Closed Access | Times Cited: 44
Page 1 - Next Page

Scroll to top